Date: 2016-02-01
Type of information: Licensing agreement
Compound: adeno-associated virus-modified volvox channelrhodopsin-1 (AAV-mVChR1)
Company: Astellas Pharma (Japan) Clino Corporation (Japan)
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases
Type agreement: license
Action mechanism:
- gene therapy. Modified Volvox channelrhodopsin-1 (mVChR1) was invented by Professor Hiroshi Tomita, currently on the Faculty of Engineering in Iwate University, and his colleagues. This is an engineered photoreceptive ion channel with the ability to respond to broad wavelengths of lights, created by modifying channelrhodopsins found in green algae. It has been shown that administration of AAV-mVChR1 in a rat model of retinitis pigmentosa results in expression of mVChR1 in retinal ganglion cells and recovery of light sensitivity of those rats, providing a possibility that AAV-mVChR1 may restore visual functions in patients with retinitis pigmentosa.
Disease: retinitis pigmentosa
Details:
- • On February 1st, 2016, Astellas Pharma and CLINO Corporation have entered into a license agreement for the worldwide development and commercialization of a gene therapy (adeno-associated virus-modified volvox channelrhodopsin-1 (AAV-mVChR1) to treat retinitis pigmentosa.
Financial terms:
Latest news:
Is general: Yes
